Care partner‐informed meaningful change thresholds for the Clinical Dementia Rating‐Sum of Boxes for trials of early Alzheimer's disease

Author:

Lansdall Claire J.1,Teng Edmond2,Chague Jerome3,Palanganda Rohan4,Delmar Paul3,Smith Janice5,Cummings Jeffrey L.6,McDougall Fiona7

Affiliation:

1. Product Development, Patient‐Centered Outcomes Research F. Hoffmann‐La Roche Ltd Basel Switzerland

2. Early Clinical Development Genentech, Inc. South San Francisco California USA

3. Product Development, Data Science F. Hoffmann‐La Roche Ltd Basel Switzerland

4. Product Development, Data Science Roche Products Ltd Welwyn Garden City UK

5. Product Development, Neuroscience Roche Products Ltd Welwyn Garden City UK

6. Chambers‐Grundy Center for Transformative Neuroscience University of Nevada Las Vegas Nevada USA

7. Product Development, Patient‐Centered Outcomes Research Genentech, Inc. South San Francisco California USA

Abstract

AbstractINTRODUCTIONConsensus definitions of meaningful within‐patient change (MWPC) on the Clinical Dementia Rating‐Sum of Boxes (CDR‐SB) are needed. Existing estimates use clinician‐rated anchors in clinically diagnosed Alzheimer's disease (AD) populations. Incorporating the care partner perspective offers important insights, and evaluating biomarker‐confirmed cohorts aligns estimates with ongoing trials.METHODSAnchor‐based analyses were conducted to evaluate MWPC on the CDR‐SB in early AD (Tauriel; NCT03289143) using Caregiver Global Impression of Change in memory or daily activities.RESULTSAcross time points and anchors, mean CDR‐SB changes associated with the “somewhat worse” category ranged from 1.50 to 2.12 in early AD, 1.07 to 2.06 in mild cognitive impairment‐AD, and 1.79 to 2.25 in mild AD.DISCUSSIONThe proposed ranges are appropriate to define meaningful progression on the CDR‐SB in similar cohorts and support the interpretation of treatment benefit through MWPC analyses. Thresholds should be calibrated to the context of use; lower/higher thresholds may be applicable in studies of earlier/later disease over shorter/longer durations.Highlights Within‐patient CDR‐SB change thresholds are provided using caregiver‐rated anchors. 1.5 to 2.5 points may be an appropriate range in early AD trials of similar durations. Cumulative distribution function plots illustrate the benefit of a given treatment. When selecting thresholds, the target population and study design should be considered.

Publisher

Wiley

Reference29 articles.

1. Interpreting patient-reported outcome results: US FDA guidance and emerging methods

2. US Food and Drug Administration (FDA).Collecting comprehensive and representative input. Accessed December 2023.https://www.fda.gov/media/139088/download

3. US Food and Drug Administration (FDA).Patient‐focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision‐making. Accessed June 2024.https://www.fda.gov/media/166830/download

4. The Clinical Dementia Rating Sum of Box Score in Mild Dementia

5. US Food and Drug Administration (FDA).Incorporating clinical outcome assessments into endpoints for regulatory decision‐making. Accessed October 2023.https://www.fda.gov/media/132505/download

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3